Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy
In colorectal cancer liver metastases (CRLM), the density of tumor-infiltrating lymphocytes, the expression of class I major histocompatibility complex (MHC-I), and the pathological response to preoperative chemotherapy have been associated with oncological outcomes after complete resection. However...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2253642 |
| _version_ | 1826914965790916608 |
|---|---|
| author | David Henault David Stephen Pierre-Antoine St-Hilaire Nouredin Messaoudi Franck Vandenbroucke-Menu Eve Simoneau Zhixia Rong Marylène Plasse Richard Létourneau André Roy Michel Dagenais Réal Lapointe Bich Nguyen Anne-Marie Mes-Masson G. Soucy Simon Turcotte |
| author_facet | David Henault David Stephen Pierre-Antoine St-Hilaire Nouredin Messaoudi Franck Vandenbroucke-Menu Eve Simoneau Zhixia Rong Marylène Plasse Richard Létourneau André Roy Michel Dagenais Réal Lapointe Bich Nguyen Anne-Marie Mes-Masson G. Soucy Simon Turcotte |
| author_sort | David Henault |
| collection | DOAJ |
| description | In colorectal cancer liver metastases (CRLM), the density of tumor-infiltrating lymphocytes, the expression of class I major histocompatibility complex (MHC-I), and the pathological response to preoperative chemotherapy have been associated with oncological outcomes after complete resection. However, the prognostic significance of the heterogeneity of these features in patients with multiple CRLMs remains under investigation. We used a tissue microarray of 220 mismatch repair-gene proficient CRLMs resected in 97 patients followed prospectively to quantify CD3+ T cells and MHC-I by immunohistochemistry. Histopathological response to preoperative chemotherapy was assessed using standard scoring systems. We tested associations between clinical, immunological, and pathological features with oncologic outcomes. Overall, 29 patients (30.2%) had CRLMs homogeneous for CD3+ T cell infiltration and MHC-I. Patients with immune homogeneous compared to heterogeneous CRLMs had longer median time to recurrence (TTR) (30 vs. 12 months, p = .0018) and disease-specific survival (DSS) (not reached vs. 48 months, p = .0009). At 6 years, 80% of the patients with immune homogeneous CRLMs were still alive. Homogeneity of response to preoperative chemotherapy was seen in 60 (61.9%) and 69 (80.2%) patients according to different grading systems and was not associated with TTR or DSS. CD3 and MHC-I heterogeneity was independent of response to pre-operative chemotherapy and of other clinicopathological variables for their association with oncological outcomes. In patients with multiple CRLMs resected with curative intent, similar adaptive immune features seen across metastases could be more informative than pathological response to pre-operative chemotherapy in predicting oncological outcomes. |
| first_indexed | 2024-03-08T17:13:26Z |
| format | Article |
| id | doaj.art-f7d6612e7f864920847bd437adcab85f |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2025-02-17T11:52:46Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-f7d6612e7f864920847bd437adcab85f2024-12-27T17:34:38ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2253642Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapyDavid Henault0David Stephen1Pierre-Antoine St-Hilaire2Nouredin Messaoudi3Franck Vandenbroucke-Menu4Eve Simoneau5Zhixia Rong6Marylène Plasse7Richard Létourneau8André Roy9Michel Dagenais10Réal Lapointe11Bich Nguyen12Anne-Marie Mes-Masson13G. Soucy14Simon Turcotte15Hepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaDepartment of Pathology, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaCancer Axis, Centre de recherche du Centre Hospitalier de l’Université de Montréal/Institut du cancer de Montréal, Montréal, Québec, CanadaCancer Axis, Centre de recherche du Centre Hospitalier de l’Université de Montréal/Institut du cancer de Montréal, Montréal, Québec, CanadaHepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaHepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaHepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaHepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaHepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaHepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaHepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaHepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaDepartment of Pathology, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaCancer Axis, Centre de recherche du Centre Hospitalier de l’Université de Montréal/Institut du cancer de Montréal, Montréal, Québec, CanadaDepartment of Pathology, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaHepato-Pancreato-Biliary Surgery Service, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaIn colorectal cancer liver metastases (CRLM), the density of tumor-infiltrating lymphocytes, the expression of class I major histocompatibility complex (MHC-I), and the pathological response to preoperative chemotherapy have been associated with oncological outcomes after complete resection. However, the prognostic significance of the heterogeneity of these features in patients with multiple CRLMs remains under investigation. We used a tissue microarray of 220 mismatch repair-gene proficient CRLMs resected in 97 patients followed prospectively to quantify CD3+ T cells and MHC-I by immunohistochemistry. Histopathological response to preoperative chemotherapy was assessed using standard scoring systems. We tested associations between clinical, immunological, and pathological features with oncologic outcomes. Overall, 29 patients (30.2%) had CRLMs homogeneous for CD3+ T cell infiltration and MHC-I. Patients with immune homogeneous compared to heterogeneous CRLMs had longer median time to recurrence (TTR) (30 vs. 12 months, p = .0018) and disease-specific survival (DSS) (not reached vs. 48 months, p = .0009). At 6 years, 80% of the patients with immune homogeneous CRLMs were still alive. Homogeneity of response to preoperative chemotherapy was seen in 60 (61.9%) and 69 (80.2%) patients according to different grading systems and was not associated with TTR or DSS. CD3 and MHC-I heterogeneity was independent of response to pre-operative chemotherapy and of other clinicopathological variables for their association with oncological outcomes. In patients with multiple CRLMs resected with curative intent, similar adaptive immune features seen across metastases could be more informative than pathological response to pre-operative chemotherapy in predicting oncological outcomes.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2253642Colorectal liver metastasisimmune scoreprognostic biomarkertumor heterogeneitytumor infiltrating lymphocytes |
| spellingShingle | David Henault David Stephen Pierre-Antoine St-Hilaire Nouredin Messaoudi Franck Vandenbroucke-Menu Eve Simoneau Zhixia Rong Marylène Plasse Richard Létourneau André Roy Michel Dagenais Réal Lapointe Bich Nguyen Anne-Marie Mes-Masson G. Soucy Simon Turcotte Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy OncoImmunology Colorectal liver metastasis immune score prognostic biomarker tumor heterogeneity tumor infiltrating lymphocytes |
| title | Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy |
| title_full | Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy |
| title_fullStr | Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy |
| title_full_unstemmed | Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy |
| title_short | Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy |
| title_sort | homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy |
| topic | Colorectal liver metastasis immune score prognostic biomarker tumor heterogeneity tumor infiltrating lymphocytes |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2253642 |
| work_keys_str_mv | AT davidhenault homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT davidstephen homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT pierreantoinesthilaire homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT nouredinmessaoudi homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT franckvandenbrouckemenu homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT evesimoneau homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT zhixiarong homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT maryleneplasse homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT richardletourneau homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT andreroy homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT micheldagenais homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT reallapointe homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT bichnguyen homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT annemariemesmasson homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT gsoucy homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy AT simonturcotte homogeneityinimmunefeaturesbetweencolorectallivermetastasesbetteridentifiespatientswithgoodprognosiscomparedtopathologicalresponsetopreoperativechemotherapy |